World Business Watch
GLOBAL BUSINESS INTELLIGENCE FOR DECISION MAKERS
Sunday, 8 November 2026
worldbusinesswatch.com

NEWS | HEALTHCARE & LIFE SCIENCES

Moderna lifts 2026 growth outlook to 15–25% after 29% Q3 jump

Moderna more than doubled its revenue growth guidance, helped by a new flu vaccine approval and positive cancer-vaccine data. It’s a sign the business is moving beyond COVID.

By **Manasee Kurlekar** | November 7, 2026



Moderna’s third-quarter revenue rose 29% to $1.313 billion, up from $1.016 billion a year earlier.

It swung to a net profit of $162 million, against a loss of $200 million in Q3 2025. Diluted EPS was $0.38, compared with a $0.51 loss.

US sales were $780 million and international sales $533 million.

The company now expects 2026 revenue to grow 15%–25%, up from its earlier forecast of up to 10%.

It also cut its R&D budget to about $2.7 billion from about $2.9 billion, and raised its year-end cash forecast to $8.1–8.3 billion from $4.7–5.2 billion.

Two milestones help diversify the business beyond COVID: US approval of the mFLUSIVA flu vaccine and positive Phase 3 results for the intismeran cancer vaccine in melanoma.

Read online: https://worldbusinesswatch.com/news/14/383/moderna-lifts-2026-growth-outlook-to-1525-after-29-q3-jump.html
© 2026 World Business Watch. All rights reserved.